Babylon launches AI-powered healthcare app to help New Yorkers

Babylon is partnering with Mount Sinai Health Partners to bring its AI-powered digital healthcare solution to New York. The smartphone app is available 24/7 and includes live chat, virtual doctor consultations and a new COVID-19 Care Assistant, which provides users with updated information and statistics related to the pandemic.

Babylon chose to launch in New York at this time to help the city as it deals with challenges—including crowded emergency rooms, misinformation and patient anxiety—related to COVID-19.

“At a time that one of the greatest cities in the world is going through one of its worst public health crises, our relationship brings the brilliant services of Mount Sinai Health Partners together with the unique global expertise of Babylon, to give eligible insurance plan members in the city access for their primary healthcare needs, wherever they are and whenever they need it,” Ali Parsa, PhD, CEO and founder of Babylon, said in a prepared statement.

“Babylon, a leader in convenient and accessible digital health care services, is a valuable addition to our high-performing primary care network,” added Robert W. Fields, MD, MHA, chief medical officer for Mount Sinai Health Partners. “New York is the epicenter of the COVID-19 pandemic and more than ever the need to engage with our patients in their homes has become an essential part of healthcare. Having Babylon in our network also strengthens our capacity in this area to serve our patients at the highest level.”

Babylon’s services are now available in New York, California and Missouri—the goal is to eventually provide care in all 50 states.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.